In addition, anti-IL6R are generally used after the failure of previous bDMARDs (i.e., TNF-α inhibitors), thus in patients with more severe and “difficult-to-treat” disease, and consequently with a higher dysregulation of the immune system and susceptibility to infections. The gene discussed is TNF; the disease is infection.